Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    More Rough Alzheimer’s News

    Man, Alzheimer’s. That’s my reaction to yesterday’s news in the field. Merck started things off with news of their last-ditch attempt to see if their beta-secretase (BACE) inhibitor verubecestat (MK-8931) could be useful. I’ve been writing about that one for a while – here’s 2012, when they announced that the com… Read More
  • Alzheimer's Disease

    Alzheimer’s and the Rare Disease Model

    Politico is a good source for national political stories, but I don’t usually look to them for coverage of drug development. But they’ve done a good job with their recent “Pharma Issue”. One of the stories (by David Freedman) is on the difficulties of Alzheimer’s drug discovery, which are legendary. The contrast betwe… Read More
  • Alzheimer's Disease

    Bad News – But Not the Unexpected Kind

    Yesterday was not a good day for small companies trying to get drugs to regulatory approval for tough diseases. You may well remember Axovant, a company that I’ve written about several times (most recently here). To recap, AXON was started by a fund manager, who bought a failed Alzheimer’s candidate off GSK, announced that they’d… Read More
  • Alzheimer's Disease

    A Movement Towards Tau in Alzheimer’s?

    Failure after failure has been the story on amyloid-targeting therapies in Alzheimer’s. Tau protein, which is involved in pathology of its own in the disease, has been less in the spotlight (although TauRx has done its part by missing its clinical endpoints with its own drug). But there’s a lot of activity going on with… Read More
  • Alzheimer's Disease

    There Are Failures, You Know

    This exact point came up around here when we last discussed FDA reform, so it’s good to see it made at length in the New England Journal of Medicine. Remember solanezumab? That was the amyloid-targeting antibody that Eli Lilly kept on investigating in trial after trial, looking for some effect on Alzheimer’s. Last November, the final… Read More
  • Alzheimer's Disease

    Neurotrope: A Shameful PR Stunt

    There was some Alzheimer’s news the other day, but it wasn’t actually about Alzheimer’s. Not very much. It was more about hype, press releases, and a grievous lack of understanding of statistics. Via @AndyBiotech and @biotechtoreador on Twitter, I came across this release about an announcement from a small company called Neurot… Read More
  • Alzheimer's Disease

    Guess How This Latest Alzheimer’s Trial Came Out

    Yes indeed, Merck announced last night that the first Phase III trial of their beta-secretase (BACE) inhibitor verubecestat was stopped because of futility. The monitoring committee, after looking over the data so far (the trial’s been running since 2012) concluded that there was no real chance of seeing efficacy. Merck had been enrolling pa… Read More
  • Alzheimer's Disease

    Eli Lilly Is a Biologics Company

    The news from Eli Lilly is not good – they’re laying off 485 people, according to filings with the state, and it appears to be completely a result of their latest Alzheimer’s clinical failures. The positions are largely in the company’s sales and marketing area. According to that article from FiercePharma, the company had be… Read More
  • Alzheimer's Disease

    Vivek Ramaswamy’s Plans

    I last wrote about Vivek Ramaswamy in the context of his first company (Axovant). That one went public on the hopes for a retread Alzheimer’s drug to work out in Phase III, and if that sounds a little iffy to you, then join a fairly large club. Alzheimer’s is truly the approach-avoidance conflict writ large: from… Read More
  • Alzheimer's Disease

    Simple, Right?

    So, name a class of prescription drugs that lots of people have been taking daily over a period of decades: how about statins? From a distance, the story is completely understandable: statins inhibit the enzyme HMG-CoA reductase, which shuts down a key step in cholesterol biosynthesis. That lowers the amount of cholesterol in the body… Read More
123...